Skip to main content

WELLS FARGO & COMPANY/MN

Position in VNDA — Vanda Pharmaceuticals Inc.

CIK 72971 SAN FRANCISCO, CA

Position in VNDA

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$314,004
+$125,141 QoQ
Shares Held
51,308
+87.7% QoQ
Ownership
0.085%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#73
of 172 holders
Holding Since
Mar 2020
26 quarters on record
Voting authority Sole 94% Shared 0% None 6%

Common Shares in VNDA Over Time

Shares Held

Position Value (USD)

Derivatives in VNDA

reported options exposure · as of Jun 30, 2020
CallValue
$0
CallShares
45,700
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

WELLS FARGO & COMPANY/MN holds $1,567,775,023 across 417 Biotechnology names. VNDA ranks #214 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in VNDA

Export CSV
35 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $314,004 51,308
2026-03-31 $188,863 27,332
2025-12-31 $606,312 68,743
2025-09-30 $244,479 48,994
2025-06-30 $186,774 39,571
2025-03-31 $174,484 38,014
2024-12-31 $160,507 33,509
2024-09-30 $122,737 26,170
2024-06-30 $144,344 25,548
2024-03-31 $84,118 20,467
2023-12-31 $74,692 17,700
2023-09-30 $62,767 14,530
2023-06-30 $410,416 62,279
2023-03-31 $351,829 51,816
2022-12-31 $14,667 1,985
2022-09-30 $44,892 4,544
2022-06-30 $54,531 5,003
2022-03-31 $971,618 85,908
2021-12-31 $1,583,167 100,903
2021-09-30 $5,329,390 310,933
2021-06-30 ALXN 904,290
2021-06-30 $8,952,459 416,200
2021-03-31 ALXN 566,241
2021-03-31 $2,201,449 146,568
2020-12-31 ALXN 873,464
2020-12-31 $1,849,006 140,716
2020-09-30 ALXN 924,664
2020-09-30 $1,286,595 133,188
2020-06-30 ALXN 999,778
2020-06-30 ALXN 45,700
2020-06-30 $1,627,337 142,250
2020-03-31 ALXN 45,700
2020-03-31 ALXN 45,800
2020-03-31 ALXN 1,338,969
2020-03-31 $2,035,624 196,489